Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 6 (2009), Issue 1 (January)

1. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.
   Cancer Res, 69(1): 161-70. [Abstract] [Full-text]
2. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
   Ophthalmology, 116(1): 57-65.e5. [Abstract] [Full-text]
3. Prospective clinical trial evaluating the efficacy of photodynamic therapy for symptomatic circumscribed choroidal hemangioma.
   Ophthalmology, 116(1): 100-105.e1. [Abstract] [Full-text]
4. Long-term effectiveness of early administration of glycoprotein IIb/IIIa agents to real-world patients undergoing primary percutaneous interventions: results of a registry study in an ST-elevation myocardial infarction network.
   Eur Heart J, 30(1): 33-43. [Abstract] [Full-text]
5. Medication effects on the rate of orthodontic tooth movement: a systematic literature review.
   Am J Orthod Dentofacial Orthop, 135(1): 16-26. [Abstract] [Full-text]
6. ST resolution 1 hour after fibrinolysis for prediction of myocardial infarct size: insights from ASSENT 3.
   Am J Cardiol, 103(2): 154-8. [Abstract] [Full-text]
7. Get With the Guidelines-Stroke is associated with sustained improvement in care for patients hospitalized with acute stroke or transient ischemic attack.
   Circulation, 119(1): 107-15. [Abstract] [Full-text]
8. Emerging intra-articular drug delivery systems for the temporomandibular joint.
   Methods, 47(2): 134-40. [Abstract] [Full-text]
9. A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer.
   Br J Cancer, 100(1): 37-43. [Abstract] [Full-text]
10. Irinotecan plus carboplatin for patients with carcinoma of unknown primary site.
    Br J Cancer, 100(1): 50-5. [Abstract] [Full-text]
11. Efficacy of graduated compression stockings for an additional 3 weeks after sclerotherapy treatment of reticular and telangiectatic leg veins.
    Dermatol Surg, 35(1): 53-7; discussion 57-8. [Abstract] [Full-text]
12. Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial.
    Br J Cancer, 100(1): 44-9. [Abstract] [Full-text]
13. Increased levels of CA 125 and CA 19.9 serum tumour markers following cyclic combined hormone replacement therapy.
    J Clin Pharm Ther, 34(1): 129-32. [Abstract] [Full-text]
14. Use of Tris-hydroxymethyl aminomethane in severe lactic acidosis due to highly active antiretroviral therapy: a case report.
    J Clin Pharm Ther, 34(1): 119-23. [Abstract] [Full-text]
15. Pre-admission therapy for childhood acute diarrhoea--a hospital-based study.
    J Clin Pharm Ther, 34(1): 55-60. [Abstract] [Full-text]
16. A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India.
    J Clin Pharm Ther, 34(1): 33-40. [Abstract] [Full-text]
17. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options.
    Clin Infect Dis, 48(3): 328-37. [Abstract] [Full-text]
18. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384.
    Clin Infect Dis, 48(3): 350-61. [Abstract] [Full-text]
19. Dangerous halo after neoadjuvant chemotherapy and two-step hepatectomy for colorectal liver metastases.
    Br J Surg, 96(1): 95-103. [Abstract] [Full-text]
20. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer.
    Br J Surg, 96(1): 26-33. [Abstract] [Full-text]
21. Combination chemotherapy with cisplatin and irinotecan in patients with adenocarcinoma of the small intestine.
    Gastric Cancer, 11(4): 201-5. [Abstract] [Full-text]
22. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
    BMC Cancer, 8: 374. [Abstract] [Full-text]
23. Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
    J Clin Oncol, 27(2): 227-34. [Abstract] [Full-text]
24. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
    J Clin Oncol, 27(2): 199-205. [Abstract] [Full-text]
25. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
    J Clin Oncol, 27(2): 235-41. [Abstract] [Full-text]
26. Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma.
    J Clin Oncol, 27(2): 242-9. [Abstract] [Full-text]
27. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.
    J Clin Oncol, 27(2): 264-70. [Abstract] [Full-text]
28. Triple receptor-negative breast cancer: the effect of race on response to primary systemic treatment and survival outcomes.
    J Clin Oncol, 27(2): 220-6. [Abstract] [Full-text]
29. FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation.
    Eur J Haematol, 82(2): 143-7. [Abstract] [Full-text]
30. Preparation and drug controlled-release of polyion complex micelles as drug delivery systems.
    Colloids Surf B Biointerfaces, 68(2): 218-24. [Abstract] [Full-text]
31. The targeting of 14-succinate triptolide-lysozyme conjugate to proximal renal tubular epithelial cells.
    Biomaterials, 30(7): 1372-81. [Abstract] [Full-text]
32. Galactosylated fluorescent labeled micelles as a liver targeting drug carrier.
    Biomaterials, 30(7): 1363-71. [Abstract] [Full-text]
33. Soft contact lenses functionalized with pendant cyclodextrins for controlled drug delivery.
    Biomaterials, 30(7): 1348-55. [Abstract] [Full-text]
34. Composite microparticle drug delivery systems based on chitosan, alginate and pectin with improved pH-sensitive drug release property.
    Colloids Surf B Biointerfaces, 68(2): 245-9. [Abstract] [Full-text]
35. Molecular basis of improved immunogenicity in DNA vaccination mediated by a mannan based carrier.
    Biomaterials, 30(7): 1389-400. [Abstract] [Full-text]
36. High-pressure NMR characterization of triacetyl-beta-cyclodextrin in supercritical carbon dioxide.
    Magn Reson Chem, 47(2): 133-41. [Abstract] [Full-text]
37. Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy.
    Crit Rev Oncol Hematol, 69(2): 108-24. [Abstract] [Full-text]
38. Effect of alginate-pectin composition on drug release characteristics of microcapsules.
    J Microencapsul, 26(2): 143-53. [Abstract] [Full-text]
39. Development of a novel nanocapsule formulation by emulsion-diffusion combined with high hydrostatic pressure.
    J Microencapsul, 26(2): 122-9. [Abstract] [Full-text]
40. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial.
    Arch Ophthalmol, 127(1): 13-21. [Abstract] [Full-text]
41. A randomized controlled trial of superior and inferior temporomandibular joint space injection with hyaluronic acid in treatment of anterior disc displacement without reduction.
    J Oral Maxillofac Surg, 67(2): 357-61. [Abstract] [Full-text]
42. Sclerotherapy of microcystic lymphatic malformations in oral and facial regions.
    J Oral Maxillofac Surg, 67(2): 251-6. [Abstract] [Full-text]
43. Nurse staffing and medication errors: cross-sectional or longitudinal relationships?
    Res Nurs Health, 32(1): 18-30. [Abstract] [Full-text]
44. Nanofibers as carrier systems for antimicrobial microemulsions. Part I: fabrication and characterization.
    Langmuir, 25(2): 1154-61. [Abstract] [Full-text]
45. Modular synthesis of functional nanoscale coordination polymers.
    Angew Chem Int Ed Engl, 48(4): 650-8. [Abstract] [Full-text]
46. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy.
    Proc Natl Acad Sci U S A, 106(2): 474-9. [Abstract] [Full-text]
47. Highly active antiretroviral therapy and increased use of contraceptives among HIV-positive women during expanding access to antiretroviral therapy in Mbarara, Uganda.
    Am J Public Health, 99(2): 340-7. [Abstract] [Full-text]
48. Cranberry or trimethoprim for the prevention of recurrent urinary tract infections? A randomized controlled trial in older women.
    J Antimicrob Chemother, 63(2): 389-95. [Abstract] [Full-text]
49. Multivalent scaffolds for affinity maturation of small molecule cell surface binders and their application to prostate tumor targeting.
    J Med Chem, 52(2): 544-50. [Abstract] [Full-text]
50. Photodynamic molecular beacon triggered by fibroblast activation protein on cancer-associated fibroblasts for diagnosis and treatment of epithelial cancers.
    J Med Chem, 52(2): 358-68. [Abstract] [Full-text]
51. Comparative positron-emission tomography (PET) imaging and phototherapeutic potential of 124I- labeled methyl- 3-(1'-iodobenzyloxyethyl)pyropheophorbide-a vs the corresponding glucose and galactose conjugates.
    J Med Chem, 52(2): 445-55. [Abstract] [Full-text]
52. MAP dendrimer elicits antibodies for detecting rat and mouse GH-binding proteins.
    J Pept Sci, 15(2): 78-88. [Abstract] [Full-text]
53. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376).
    Pediatr Blood Cancer, 52(3): 346-50. [Abstract] [Full-text]
54. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941.
    Pediatr Blood Cancer, 52(3): 335-9. [Abstract] [Full-text]
55. Contraceptive hormone use and cardiovascular disease.
    J Am Coll Cardiol, 53(3): 221-31. [Abstract] [Full-text]
56. Neoadjuvant treatment with single-agent cetuximab followed by 5-FU, cetuximab, and pelvic radiotherapy: a phase II study in locally advanced rectal cancer.
    Int J Radiat Oncol Biol Phys, 73(2): 466-72. [Abstract] [Full-text]
57. Assessing the impact of drug use on hospital costs.
    Health Serv Res, 44(1): 128-44. [Abstract] [Full-text]
58. Nicotine induces resistance to chemotherapy by modulating mitochondrial signaling in lung cancer.
    Am J Respir Cell Mol Biol, 40(2): 135-46. [Abstract] [Full-text]
59. Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors.
    Gynecol Oncol, 112(2): 394-9. [Abstract] [Full-text]
60. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Gynecol Oncol, 112(2): 337-41. [Abstract] [Full-text]
61. The price of success: cost-effectiveness of molecularly targeted agents.
    Clin Pharmacol Ther, 85(2): 136-8. [Abstract] [Full-text]
62. The volume of lactated Ringer's solution required to maintain preload and cardiac index during open and laparoscopic surgery.
    Anesth Analg, 108(2): 616-22. [Abstract] [Full-text]
63. Resistance pattern of cytomegalovirus (CMV) after oral valganciclovir therapy in transplant recipients at high-risk for CMV infection.
    Antiviral Res, 81(2): 174-9. [Abstract] [Full-text]
64. Drug-target identification from total cellular lysate by drug-induced conformational changes.
    Anal Biochem, 385(2): 314-20. [Abstract] [Full-text]
65. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy.
    Int J Cancer, 124(6): 1457-62. [Abstract] [Full-text]
66. Light-activated cytotoxic compounds from Malaysian microorganisms for photodynamic therapy of cancer.
    Antonie Van Leeuwenhoek, 95(2): 179-88. [Abstract] [Full-text]
67. Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis.
    Proc Natl Acad Sci U S A, 106(3): 685-90. [Abstract] [Full-text]
68. Targeting nanodisks via a single chain variable antibody--apolipoprotein chimera.
    Biochem Biophys Res Commun, 379(2): 466-9. [Abstract] [Full-text]
69. Ramosetron for the prevention of nausea and vomiting during 5-fluorouracil-based chemoradiotherapy for pancreatico-biliary cancer.
    Jpn J Clin Oncol, 39(2): 111-5. [Abstract] [Full-text]
70. Balloon tamponade of hemorrhage after uterine curettage for gestational trophoblastic disease.
    Obstet Gynecol, 113(2): 557-60. [Abstract] [Full-text]
71. Cervical vasopressin compared with no premedication and blood loss during vaginal hysterectomy: a randomized controlled trial.
    Obstet Gynecol, 113(2): 313-8. [Abstract] [Full-text]
72. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis.
    J Acquir Immune Defic Syndr, 50(2): 148-52. [Abstract] [Full-text]
73. Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children.
    J Acquir Immune Defic Syndr, 50(2): 182-91. [Abstract] [Full-text]
74. Efficacy of high vs low dose TNF-isolated limb perfusion for locally advanced soft tissue sarcoma.
    Eur J Surg Oncol, 35(2): 209-14. [Abstract] [Full-text]
75. Intracellular delivery of proteins into mouse Müller glia cells in vitro and in vivo using Pep-1 transfection reagent.
    J Neurosci Methods, 177(2): 403-19. [Abstract] [Full-text]
76. Significant delivery of tacrine into the brain using magnetic chitosan microparticles for treating Alzheimer's disease.
    J Neurosci Methods, 177(2): 427-33. [Abstract] [Full-text]
77. Targeted delivery of pharmacological agents into rat dorsal root ganglion.
    J Neurosci Methods, 177(2): 397-402. [Abstract] [Full-text]
78. Focal macromolecule delivery in neuronal tissue using simultaneous pressure ejection and local electroporation.
    J Neurosci Methods, 177(2): 273-84. [Abstract] [Full-text]
79. Achieving synaptically relevant pulses of neurotransmitter using PDMS microfluidics.
    J Neurosci Methods, 177(2): 294-302. [Abstract] [Full-text]
80. Minimising medication errors in children.
    Arch Dis Child, 94(2): 161-4. [Abstract] [Full-text]
81. Multiscale modeling of dendrimers and their interactions with bilayers and polyelectrolytes.
    Molecules, 14(1): 423-38. [Abstract] [Full-text]
82. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation.
    J Med Virol, 81(3): 400-5. [Abstract] [Full-text]
83. Prognostic factors of long-term CD4+count-guided interruption of antiretroviral treatment.
    J Med Virol, 81(3): 481-7. [Abstract] [Full-text]
84. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy.
    J Med Virol, 81(3): 441-5. [Abstract] [Full-text]
85. Outcomes of antifungal prophylaxis in high-risk liver transplant recipients.
    Transpl Infect Dis, 11(1): 40-8. [Abstract] [Full-text]
86. Protocols for Paget-Schroetter syndrome and late treatment of chronic subclavian vein obstruction.
    Ann Thorac Surg, 87(2): 416-22. [Abstract] [Full-text]
87. Impact of age, leukocyte count and day 21-bone marrow response to chemotherapy on the long-term outcome of children with philadelphia chromosome-positive acute lymphoblastic leukemia in the pre-imatinib era: results of the FRALLE 93 study.
    BMC Cancer, 9: 14. [Abstract] [Full-text]
88. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery.
    Biomaterials, 30(8): 1627-34. [Abstract] [Full-text]
89. A unified mathematical model for the prediction of controlled release from surface and bulk eroding polymer matrices.
    Biomaterials, 30(8): 1657-64. [Abstract] [Full-text]
90. Akt1 silencing efficiencies in lung cancer cells by sh/si/ssiRNA transfection using a reductable polyspermine carrier.
    Biomaterials, 30(8): 1635-47. [Abstract] [Full-text]
91. Comparison of outcomes and safety of "facilitated" versus primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction.
    Am J Cardiol, 103(3): 316-21. [Abstract] [Full-text]
92. Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience.
    J Surg Oncol, 99(2): 109-13. [Abstract] [Full-text]
93. r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans.
    Eur J Endocrinol, 160(2): 173-6. [Abstract] [Full-text]
94. Thermo-triggered and biotinylated biotin-P(NIPAAm-co-HMAAm)-b-PMMA micelles for controlled drug release.
    J Biomed Mater Res A, 88(3): 814-22. [Abstract] [Full-text]
95. Behavior of fluorescent molecules bound to the interior of silica nanocapsules in various solvents.
    J Colloid Interface Sci, 331(2): 507-13. [Abstract] [Full-text]
96. IR spectroscopy investigation using DFT analysis on the structure of P(1) phosphorus dendrimer built from octasubstituted metal-free phthalocyanine core.
    Spectrochim Acta A Mol Biomol Spectrosc, 72(3): 636-42. [Abstract] [Full-text]
97. When is thrombolysis for acute lower limb ischemia worthwhile?
    Eur J Vasc Endovasc Surg, 37(2): 206-12. [Abstract] [Full-text]
98. Liposome encapsulated polyethylenimine/ODN polyplexes for brain targeting.
    J Control Release, 133(3): 230-7. [Abstract] [Full-text]
99. Delivery of rapamycin to dendritic cells using degradable microparticles.
    J Control Release, 133(3): 191-7. [Abstract] [Full-text]
100. Enhanced photodynamic cancer treatment by supramolecular nanocarriers charged with dendrimer phthalocyanine.
     J Control Release, 133(3): 245-51. [Abstract] [Full-text]
101. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice.
     J Control Release, 133(3): 172-7. [Abstract] [Full-text]
102. Does study enrollment delay treatment with intravenous thrombolytics for acute ischemic stroke?
     Stroke, 40(2): 663. [Abstract] [Full-text]
103. Factor v leiden mutation in reocclusion after intra-arterial thrombolysis.
     Stroke, 40(2): 660-2. [Abstract] [Full-text]
104. Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence.
     Breast Cancer Res Treat, 114(1): 103-12. [Abstract] [Full-text]
105. Oncogenic H-Ras and PI3K signaling can inhibit E-cadherin-dependent apoptosis and promote cell survival after photodynamic therapy in mouse keratinocytes.
     J Cell Physiol, 219(1): 84-93. [Abstract] [Full-text]
106. Complete remission of platinium refractory ovarian cancer with second line tegafur with uracil monotherapy: a case report.
     Cancer Chemother Pharmacol, 63(4): 745-8. [Abstract] [Full-text]
107. Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy.
     Cancer Chemother Pharmacol, 63(4): 731-43. [Abstract] [Full-text]
108. Efficacy of intravitreal and periocular triamcinolone associated with photodynamic therapy for treatment of retinal angiomatous proliferation.
     Br J Ophthalmol, 93(2): 166-70. [Abstract] [Full-text]
109. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
     JAMA, 301(4): 393-403. [Abstract] [Full-text]
110. Self-medication prevalence for sexually transmitted diseases: meta-analysis and meta-regression of population level determinants.
     Sex Transm Dis, 36(2): 112-9. [Abstract] [Full-text]
111. Probing the lactose.GM3 carbohydrate-carbohydrate interaction with glycodendrimers.
     Org Lett, 11(3): 559-62. [Abstract] [Full-text]
112. Knocking down barriers: advances in siRNA delivery.
     Nat Rev Drug Discov, 8(2): 129-38. [Abstract] [Full-text]
113. Mechanisms of drug combinations: interaction and network perspectives.
     Nat Rev Drug Discov, 8(2): 111-28. [Abstract] [Full-text]
114. Chloride channels as drug targets.
     Nat Rev Drug Discov, 8(2): 153-71. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.